Study Overview

This extension study follows patients who successfully completed the CT‑AMT‑060‑01 clinical trial, tracking from the first visit at 5.5 years post‑dose to the final visit at 10 years. Because the design is open‑label, both participants and investigators are aware of the treatment administered.

Population and Therapeutic Context

The study enrolls individuals with severe or moderate hemophilia B. Current standard of care consists of factor IX replacement products, including conventional and extended‑half‑life formulations. AAV5‑hFIX utilizes an adeno‑associated virus serotype 5 vector to deliver the FIX gene, aiming for sustained protein expression after a single administration.

Differentiation and Expected Benefits

While traditional replacement therapy requires regular infusions, gene therapy is intended to provide long‑term FIX production from a one‑time dose. Long‑term follow‑up will assess immune responses, hepatic safety, and durability of FIX activity, enabling a clear comparison of safety and efficacy relative to existing therapies.

Potential Industry Impact

If the results are favorable, CSL Behring’s pipeline valuation could increase, and the competitive landscape of the hemophilia B market may shift. Moreover, the long‑term data will serve as critical evidence for regulatory submissions and could become a benchmark for other AAV‑based gene‑therapy programs.